Shunho股份新型烟草方向发展规划说明

Oct.29.2024
Shunho股份新型烟草方向发展规划说明
Shunho股份回应投资者关于新型烟草方向的提问,并透露公司在该领域的发展规划。

On October 29th, an investor asked Shunho Corporation (002565) on an interactive platform about the company's technological reserves in the new tobacco direction. The investor noted that the actual annual revenue in this area is very small compared to expectations, and asked about the company's further planning in the new tobacco direction and how they plan to expand and strengthen related businesses. The investor also inquired about the current operating situation of Green E-Cigarette Technology, a joint venture between Shunho Corporation and Dongfeng Group, and whether there is potential for further collaboration. The investor raised the possibility of merging the two Hong Kong-listed companies involved in tobacco packaging and asked about Shunho Corporation's views and expectations on mergers and restructuring.


In response, Shunho Corporation stated:


The company is expanding its business in the new tobacco product sector through wholly-owned, controlling, and equity-participating companies, forming an industrial system. Currently, the company's controlling subsidiary Shenzhen Green Fresh has obtained the "Tobacco Monopoly Production Enterprise License" for e-cigarette OEM enterprises, while the equity-participating subsidiary Meizhonglian has obtained the "Tobacco Monopoly Production Enterprise License" for e-cigarette product manufacturers, and the company's wholly-owned subsidiary Shunho Yilong has obtained the "Tobacco Monopoly Production Enterprise License" for e-cigarette brand holders for domestic sales. Its "Yilong" brand e-cigarettes have successfully entered some retail stores in Beijing, Shenzhen, and Shanghai. The acquisition of the relevant licenses has further promoted the company's compliance layout in the new tobacco industry. In the future, the company will focus its efforts domestically, promoting the listing and sales of its e-cigarette brand "Yilong," actively seeking and strengthening cooperation opportunities with China Tobacco customers. On the other hand, it will also vigorously promote overseas processing and export business, establish a sound overseas sales network, and continuously explore overseas development and operation models.


The company currently holds a 60% stake in Shanghai Lvxin Electronic Technology Co., Ltd., with the remaining 40% owned by Guangdong Dongfeng New Materials Group Co., Ltd. The company is actively engaged in research and development, production, and branding of new tobacco products domestically and internationally. The company's controlling subsidiary, Shanghai Lvxin, serves as the main entity and platform for the implementation of new tobacco product-related businesses. Currently, Shanghai Lvxin Electronic is operating normally, and specific data related to its operations and strategic planning can be found in the company's relevant periodic reports.


The company pays close attention to the relevant policies issued by the government and actively monitors and studies the trends of these policies. The company always prioritizes the protection of the legitimate rights and interests of all shareholders, upholding an attitude of open cooperation for mutual benefit. In the future, the company will make strategic plans and layouts based on actual situations, industry characteristics, and market demands, continuously monitoring market opportunities and promoting high-quality development through appropriate capital operations. In the event of major events such as mergers and reorganizations, the company will fulfill its disclosure obligations in a timely manner in accordance with relevant regulations.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10